The expert says that Life Science Co.’s technical setup is extremely positive and continues to get better

Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks the technical setup of this company is extremely positive.


You may remember me bumping around Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) for weeks. There was a reason for that as it continued to double since we bought it in July, and there’s a reason to be buzzing about Awakn Life Sciences Corp. (AWKN:NEO; AWKNF:OTCQB) now, this reason is that its technical setup is extremely positive and continues to improve.

Therefore, Awakn is considered to be an even stronger buy than when we last looked at it, and this is a buy that is considered worth going overweight, and US subscribers can be pleased to know that there is acceptable liquidity in US OTC market.

On its latest 6-month chart, we can see that it is in the process of completing the second low of a double bottom and also that the volume pattern is very positive with continued large buys since mid- August which has pushed the volume indicators much higher – Accum – Distribut is shown in this chart and Balanced Volume in the 15-month chart further down the page.

This is a sign of accumulation set by buyers who “know something” and we don’t have to know what they know, just follow in their footsteps.

The flattening of the 50-day moving average and the appearance of a bullish “dragonfly Doji” candlestick on the chart on Thursday suggests that it is time for it to break higher, so there could be some positive news soon.

The 15-month chart shows the stock’s entire history, and on it, we can see that Awakn is not only completing the second low of a double bottom, but is on the cusp of breaking out of the strong downtrend in force from January.

In this chart, which is arithmetic, the On-balance Volume line has been added to the top, and as we can see, it is strong and already making new highs despite the continued very low stock price.

This is indeed a very positive divergence, implying that we will soon see an upside breakout.

Therefore, Awakn is considered to be an even stronger buy than when we last looked at it, and this is a buy that is considered worth going overweight, and US subscribers can be pleased to know that there is acceptable liquidity in US OTC market.

Awakn is thought to be a good destination for any funds freed up by our gain on BioLargo in late Friday trading, where we made a quick 40% gain in less than two weeks.

Even if it turns out that we sold BioLargo Inc. (BLGO:OTCQB) very quickly, it doesn’t matter as we came out with a nice quick profit at a time when the risk was increasing rapidly.

Awakn Life Sciences Corp. website.

Awakn Life Sciences Corp. closed at CA$0.57, $0.42 on September 9, 2022.


Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment idea? Sign up to receive free Streetwise Reports’ newspaper.

Subscribe

Discoveries of CliveMaund.com

The above represents the opinion and analysis of Mr. Maund, based on the data available to him at the time of writing. The thoughts of Mr. Maund are his own and are not a recommendation or an offer to buy or sell securities. Mr. Maund is an independent analyst who receives no compensation of any kind from any group, individual or corporation mentioned in his reports. Since trading and investing in any financial market can involve serious risk of loss, Mr. Maund recommends that you consult a qualified investment advisor, one licensed by the appropriate regulatory agencies in your legal jurisdiction, and do your due diligence and research when entering into any type of transaction with financial consequences. Although a qualified and experienced stock market analyst, Clive Maund is not a registered securities adviser. Therefore, the opinions of Mr. Maund for the market and shares can only be interpreted as a request to buy and sell securities when they are subject to the approval and prior approval of a Registered Securities Adviser acting in accordance with the relevant regulations in your area of ​​jurisdiction.

Discoveries:
1) Clive Maund: I, or members of my family or immediate family, own securities of the following companies mentioned in this article: None. I personally or my immediate family or family members are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are Streetwise Reports billboard sponsors: Awakn Life Sciences Corp. AND Algernon Pharmaceuticals Inc. Click here for important information about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Algernon Pharmaceuticals Inc. Please click here for more information.

3) Statements and opinions expressed are those of the author and not of Streetwise Reports or its officers. The author is fully responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or distribute this article. Streetwise Reports requires contributing authors to disclose any holdings or economic relationships with the companies they write about. Streetwise Reports relies on the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.

4) This article does not constitute investment advice. Each reader is encouraged to consult his or her own individual financial professional and any action the reader takes as a result of the information presented herein is his or her own responsibility. By accessing this page, each reader accepts and agrees to the Streetwise Reports terms of use and full legal disclaimer. This article is not an investment solicitation. Streetwise Reports does not provide general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned in Streetwise Reports.

5) From time to time, Streetwise Reports LLC and their directors, officers, employees or family members, as well as persons interviewed for articles and interviews on the site, may have a long or short position in the securities mentioned . Directors, officers, employees or members of their immediate families are prohibited from buying and/or selling these securities on the open market or otherwise from the moment of the decision to publish an article until three business days after publication of the article. The above prohibition does not apply to articles that essentially merely restate previously published company releases. As of the date hereof, the officers and/or employees of Streetwise Reports LLC (including their family members) own securities of Awakn Life Sciences Corp. and Algernon Pharmaceuticals Inc., company mentioned in this article.

6) This article does not constitute medical advice. Streetwise Reports officers, employees and contributors are not licensed medical professionals. Readers should always contact their health care professionals for medical advice.

Leave a Comment